Vosoritide

Achondroplasia is caused by a gain-of-function mutation in FGFR3 that constitutively activates the RAF-MEK-ERK arm of MAPK signalling in growth-plate chondrocytes, suppressing their proliferation and differentiation. C-type natriuretic peptide acting through NPR-B raises cyclic GMP and activates protein kinase G, which inhibits RAF-1 and therefore dampens that same MAPK pathway. Native CNP is destroyed by neutral endopeptidase within about two minutes, so vosoritide was engineered with a 15-residue N-terminal extension that resists NEP cleavage while preserving NPR-B binding, extending the half-life enough for once-daily dosing. In the phase 3 trial annualised growth velocity increased by about 1.6 cm per year versus placebo, and open-label extension data show the effect persists for years.

Targets: Natriuretic peptide receptor B, Cyclic GMP and PKG signalling, FGFR3-MAPK pathway in chondrocytes

• · Weight-based at approximately 15 mcg per kg once daily, with the label specifying exact vial size and volume per weight band. A 15 kg child receives roughly 240 mcg. The dose is recalculated as the child grows.

Work out your exact syringe units →

• very commonInjection-site reactions: erythema, swelling, pain— Reported in the majority of children; rarely a reason to stop.
• commonTransient decrease in blood pressure— Expected from natriuretic peptide pharmacology. Food and fluid before dosing mitigate it.
• commonVomiting
• commonDizziness and fatigue— Usually within the first hour after injection.
• commonArthralgia

• Closed epiphyses, where there is no growth plate left to act on
• Severe cardiac or vascular disease where a fall in blood pressure would be dangerous
• Hypersensitivity to vosoritide

• cautionsomatropin — Growth hormone is not established as adding benefit in achondroplasia and combination use is not supported by trial data.

• · Height and growth velocity at least every 3 to 6 months
• · Blood pressure and heart rate, particularly early in therapy
• · Radiographic assessment of growth plate status
• · Weight, to keep the dose correct

Prescription drug approved in the US, EU and elsewhere for achondroplasia in children with open epiphyses.

• Voxzogo FDA prescribing information (label)
• Savarirayan et al. 2020 Lancet, randomised phase 3 trial of vosoritide in children with achondroplasia (trial)

Achondroplasia is a gain-of-function disease, not a loss-of-function one, and that dictates everything about how the drug works. The recurrent G380R mutation in FGFR3 leaves the receptor constitutively active, and the arm that matters for growth is RAS-RAF-MEK-ERK in the proliferative zone of the growth plate. Overactive ERK suppresses chondrocyte proliferation and delays hypertrophic differentiation, so the growth plate produces less cartilage template and endochondral bone growth stalls, most severely in the proximal limb segments. CNP is the physiological counterweight to that pathway. Acting through NPR-B, a receptor guanylyl cyclase rather than a GPCR, it raises intracellular cyclic GMP, activates protein kinase G type II, and PKG phosphorylates and inhibits RAF-1, cutting the MAPK cascade upstream of MEK. That is a direct molecular brake on the exact pathway the mutation has jammed open. The engineering problem was that native CNP has a half-life of about two minutes because neutral endopeptidase attacks its N-terminus; adding a 15-residue extension blocks that without disturbing the C-terminal ring that NPR-B actually reads, buying enough exposure for once-daily dosing. Note that even the engineered molecule has a 21 to 28 minute half-life, so this is a daily pulse rather than continuous coverage, and it works because growth plate chondrocytes integrate the signal over days. NPR-B is also expressed on vascular smooth muscle, where the same cyclic GMP rise causes vasodilation, which is exactly why transient hypotension is an expected effect and why the label asks for food and fluid before the injection.

The most common practical failure is measurement. An effect of 1.6 cm per year cannot be detected by a tape measure against a doorframe, and inconsistent stadiometry generates both false disappointment and false reassurance. The second is the reconstitution and timing routine: sterile water only, gentle swirling, use within 3 hours at room temperature, given about 30 minutes after a meal with fluid. Skipping the food and fluid step is the usual reason a child feels dizzy afterwards. The third is treating outside the licensed window, either before the growth plates are relevant or after they have closed, at which point the drug does nothing. The fourth is expectation management, which is the hardest part: the drug increases growth velocity, and whether that converts into meaningful adult height or fewer achondroplasia complications is still being followed in extension studies. Families making a decision about years of daily injections in a small child deserve that stated plainly rather than buried. The fifth is injection-site reactions, which occur in the majority of children and are almost never a reason to stop but are a daily burden nobody warns about adequately.

1. 240 mcgOngoing, weight-banded — Approximately 15 mcg per kilogram once daily. A 15 kg child receives roughly 240 mcg. The label specifies the exact vial size and injection volume per weight band rather than asking anyone to calculate it. Give about 30 minutes after a meal with adequate fluid, to blunt the blood pressure drop, and rotate sites.
2. —Recalculated as the child grows — The dose is adjusted for weight only, never for response. There is no escalation ladder in the usual sense; the vial strength changes as the child moves between weight bands. Reconstitute with the supplied sterile water, not bacteriostatic water, swirl gently, and use within 3 hours at room temperature or 12 hours refrigerated.

• Natriuretic peptide receptor B (NPR-B, guanylyl cyclase B) on growth plate chondrocytes — High; numeric affinity not resolved this session.

  Particulate guanylyl cyclase activity raises intracellular cyclic GMP, activating PKG-II, which inhibits RAF-1 and dampens the constitutively overactive FGFR3-RAS-MEK-ERK cascade. Chondrocyte proliferation and hypertrophic differentiation resume.

• NPR-B on vascular smooth muscle — High

  Cyclic GMP-mediated vasodilation, producing the transient blood pressure fall, dizziness and occasional fatigue seen in the first hour after injection.

• NPR-C (clearance receptor) — Binds, as natriuretic peptides generally do

  Contributes to clearance rather than signalling.

• Savarirayan 2020 phase 3 vosoritide trial Phase 3, randomised, double-blind, placebo-controlled, multicentre · 52 weeks · 2020

  Change from baseline in annualised growth velocity in children with achondroplasia. Vosoritide increased annualised growth velocity by roughly 1.6 cm per year versus placebo, the first demonstration of an effective pharmacological therapy for the condition.

• Phase 3 extension, 2-year results Open-label extension · 104 weeks · 2021

  Persistence of the growth-promoting effect and safety over 2 years. The growth velocity benefit was sustained rather than transient, which was the key open question after the 52-week result.

There is nothing to feel. Growth velocity changes are only measurable over 6 to 12 months, and the 52-week trial endpoint reflects that. Transient dizziness or blood pressure drop occurs within the first hour after injection and settles. Injection-site erythema appears from the first weeks. Durability of the growth effect was demonstrated through 2 years and has been followed further in extension studies. Treatment continues for years, typically from infancy or early childhood to skeletal maturity.

There is no established stack. Growth hormone has been tried in achondroplasia for decades and produces a modest early height gain that largely washes out, and there is no trial evidence that combining it with vosoritide adds anything; the Core record is right to flag that as caution rather than synergy. Limb lengthening surgery is the alternative rather than a partner, and the two are not usually combined during active lengthening. The genuinely important co-management is not pharmacological at all: foramen magnum decompression where indicated in infancy, sleep-disordered breathing assessment, otitis media and hearing surveillance, and spinal stenosis monitoring. Whether vosoritide reduces the incidence of any of those complications is the real open question and it is not answered yet. Newer agents in the same space, including infigratinib as an oral FGFR3 inhibitor, are in development and would be alternatives rather than additions.

Against growth hormone: growth hormone was the previous pharmacological attempt in achondroplasia and produced a modest early gain that largely dissipated, because it acts on a pathway the FGFR3 mutation is downstream of. Vosoritide acts on the jammed pathway itself, which is why it is the first therapy with a defensible mechanism. Against surgical limb lengthening: lengthening produces far larger height gains, up to many centimetres, but at the cost of months to years in external fixators, substantial pain, and real complication rates, and it does not address foramen magnum stenosis or any other axial problem. Against doing nothing: a legitimate choice, and one a meaningful part of the community with dwarfism actively argues for, on the grounds that achondroplasia is a difference rather than a disease to be corrected. That argument deserves engaging with rather than dismissing, particularly since the medical complications the drug might plausibly prevent, spinal stenosis and foramen magnum compression, have not yet been shown to be reduced by it.

Ultra-orphan pricing, widely reported to run to hundreds of thousands of dollars per year in the US. I did not source a figure this session and will not invent one.

• ?The one-letter sequence is assembled from the label's description, Pro-Gly plus the 37 C-terminal residues of human CNP53, rather than read off a sequence listing, so verified is false.
• ?Volume of distribution is quoted by the label as 2880 to 3020 mL/kg rather than in litres, so the litre field is null.
• ?Absolute bioavailability and protein binding are not determined.
• ?The trials' enrolments were not confirmed against the papers, so both are null. The registration trial enrolled roughly 120 children.
• ?The most important uncertainty is clinical rather than pharmacological: whether increased growth velocity translates into meaningful adult height, and whether it reduces the complications of achondroplasia, is genuinely unresolved.
• ?No cost figures were sourced.

• Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial Savarirayan R, et al., Lancet, 2020 · PMID 32891212

  The registration trial. The effect size, around 1.6 cm per year, is worth holding in mind when reading enthusiastic summaries.

• Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study Savarirayan R, et al., Genetics in Medicine, 2021 · PMID 34341520

  Answers the durability question: the effect does not wash out in year two.

• VOXZOGO (vosoritide) for injection - FDA prescribing information BioMarin Pharmaceutical, DailyMed

  Source of the 15 minute median tmax, 2880 to 3020 mL/kg apparent volume of distribution, 79.4 to 104 mL/min/kg clearance, 21 to 28 minute half-life, and the description of the molecule as Pro-Gly plus the 37 C-terminal residues of CNP53.